John A. Orwin - 17 May 2023 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Role
Director
Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact
Issuer symbol
TVTX
Transactions as of
17 May 2023
Transactions value $
$0
Form type
4
Filing time
19 May 2023, 16:05:38 UTC
Previous filing
13 Feb 2023
Next filing
02 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TVTX Common Stock Award $0 +4,500 +25.17% $0 22,375 17 May 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TVTX Stock option (right to buy) Award $0 +13,500 $0 13,500 17 May 2023 Common Stock 13,500 $17.11 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.
F2 The equity award vests over a one year period.